Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Schmid

Showing results (451-460 of 629) with videos related to

Pageof 63
Sort By:
Analytical Chemistry|November 19, 2019
TMTpro: Design, Synthesis, and Initial Evaluation of a Proline-Based Isobaric 16-Plex Tandem Mass Tag Reagent SetAndrew Thompson, Nikolai Wölmer, Sasa Koncarevic, et al.
Molecular Oncology|April 14, 2023
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapyMattea Reinisch, Simona Bruzas, Oleg Gluz, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancerPeter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 6, 2025
PSMA expression assessed by [<sup>18</sup>F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamideElena Katharina Berg, Sophie Carina Kunte, Josef Zahner, et al.
Future Oncology (London, England)|October 27, 2022
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain studyJosé Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
Toxins|September 26, 2021
Venom Immunotherapy: From Proteins to Product to Patient ProtectionMartin Feindor, Matthew D Heath, Simon J Hewings, et al.
Frontiers in Allergy|April 7, 2022
Allergic Rhinitis in Childhood and the New EUFOREA AlgorithmGlenis Kathleen Scadding, Peter Kenneth Smith, Michael Blaiss, et al.
Cancer Science|January 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup AnalysisMasato Takahashi, Hirofumi Mukai, Toshimi Takano, et al.
Contact Dermatitis|April 29, 2009
Metalworking exposures and persistent skin symptoms in the ECRHS II and SAPALDIA 2 cohortsMaria C Mirabelli, Jan-Paul Zock, Andreas J Bircher, et al.
The World Allergy Organization Journal|October 5, 2013
A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnosticsGiorgio Walter Canonica, Ignacio J Ansotegui, Ruby Pawankar, et al.
Pageof 63

Showing results (451-460 of 629) with videos related to

Sort By:
Pageof 63
Analytical Chemistry|November 19, 2019
TMTpro: Design, Synthesis, and Initial Evaluation of a Proline-Based Isobaric 16-Plex Tandem Mass Tag Reagent SetAndrew Thompson, Nikolai Wölmer, Sasa Koncarevic, et al.
Molecular Oncology|April 14, 2023
Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapyMattea Reinisch, Simona Bruzas, Oleg Gluz, et al.
Therapeutic Advances in Medical Oncology|April 29, 2025
TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancerPeter Schmid, Mafalda Oliveira, Joyce O'Shaughnessy, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|December 6, 2025
PSMA expression assessed by [<sup>18</sup>F]PSMA-1007 PET/CT imaging in metastatic hormone-sensitive prostate cancer patients treated with apalutamideElena Katharina Berg, Sophie Carina Kunte, Josef Zahner, et al.
Future Oncology (London, England)|October 27, 2022
Trastuzumab and pertuzumab without chemotherapy in early-stage HER2+ breast cancer: a plain language summary of the PHERGain studyJosé Manuel Pérez-García, Geraldine Gebhart, Manuel Ruiz Borrego, et al.
Toxins|September 26, 2021
Venom Immunotherapy: From Proteins to Product to Patient ProtectionMartin Feindor, Matthew D Heath, Simon J Hewings, et al.
Frontiers in Allergy|April 7, 2022
Allergic Rhinitis in Childhood and the New EUFOREA AlgorithmGlenis Kathleen Scadding, Peter Kenneth Smith, Michael Blaiss, et al.
Cancer Science|January 15, 2026
Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup AnalysisMasato Takahashi, Hirofumi Mukai, Toshimi Takano, et al.
Contact Dermatitis|April 29, 2009
Metalworking exposures and persistent skin symptoms in the ECRHS II and SAPALDIA 2 cohortsMaria C Mirabelli, Jan-Paul Zock, Andreas J Bircher, et al.
The World Allergy Organization Journal|October 5, 2013
A WAO - ARIA - GA²LEN consensus document on molecular-based allergy diagnosticsGiorgio Walter Canonica, Ignacio J Ansotegui, Ruby Pawankar, et al.
Pageof 63